519 related articles for article (PubMed ID: 36050585)
1. A comparison between SARS-CoV-1 and SARS-CoV2: an update on current COVID-19 vaccines.
Abdolmaleki G; Taheri MA; Paridehpour S; Mohammadi NM; Tabatabaei YA; Mousavi T; Amin M
Daru; 2022 Dec; 30(2):379-406. PubMed ID: 36050585
[TBL] [Abstract][Full Text] [Related]
2. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
[TBL] [Abstract][Full Text] [Related]
3. Perspectives on development of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Zhang C; Zhou C; Shi L; Liu G
Hum Vaccin Immunother; 2020 Oct; 16(10):2366-2369. PubMed ID: 32961082
[TBL] [Abstract][Full Text] [Related]
4. The COVID-19 pandemic: viral variants and vaccine efficacy.
Ciotti M; Ciccozzi M; Pieri M; Bernardini S
Crit Rev Clin Lab Sci; 2022 Jan; 59(1):66-75. PubMed ID: 34598660
[TBL] [Abstract][Full Text] [Related]
5. Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines.
Lambert PH; Ambrosino DM; Andersen SR; Baric RS; Black SB; Chen RT; Dekker CL; Didierlaurent AM; Graham BS; Martin SD; Molrine DC; Perlman S; Picard-Fraser PA; Pollard AJ; Qin C; Subbarao K; Cramer JP
Vaccine; 2020 Jun; 38(31):4783-4791. PubMed ID: 32507409
[TBL] [Abstract][Full Text] [Related]
6. SARS-CoV2 variant-specific replicating RNA vaccines protect from disease following challenge with heterologous variants of concern.
Hawman DW; Meade-White K; Archer J; Leventhal SS; Wilson D; Shaia C; Randall S; Khandhar AP; Krieger K; Hsiang TY; Gale M; Berglund P; Fuller DH; Feldmann H; Erasmus JH
Elife; 2022 Feb; 11():. PubMed ID: 35191378
[TBL] [Abstract][Full Text] [Related]
7. A comprehensive review of SARS-CoV-2 vaccines: Pfizer, Moderna & Johnson & Johnson.
Patel R; Kaki M; Potluri VS; Kahar P; Khanna D
Hum Vaccin Immunother; 2022 Dec; 18(1):2002083. PubMed ID: 35130825
[TBL] [Abstract][Full Text] [Related]
8. Anti-Coronavirus Vaccines: Past Investigations on SARS-CoV-1 and MERS-CoV, the Approved Vaccines from BioNTech/Pfizer, Moderna, Oxford/AstraZeneca and others under Development Against SARSCoV- 2 Infection.
Costanzo M; De Giglio MAR; Roviello GN
Curr Med Chem; 2022; 29(1):4-18. PubMed ID: 34355678
[TBL] [Abstract][Full Text] [Related]
9. The Long Road Toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization Strategies.
Frederiksen LSF; Zhang Y; Foged C; Thakur A
Front Immunol; 2020; 11():1817. PubMed ID: 32793245
[TBL] [Abstract][Full Text] [Related]
10. An overview on inactivated and live-attenuated SARS-CoV-2 vaccines.
Khoshnood S; Arshadi M; Akrami S; Koupaei M; Ghahramanpour H; Shariati A; Sadeghifard N; Heidary M
J Clin Lab Anal; 2022 May; 36(5):e24418. PubMed ID: 35421266
[TBL] [Abstract][Full Text] [Related]
11. Human and novel coronavirus infections in children: a review.
Rajapakse N; Dixit D
Paediatr Int Child Health; 2021 Feb; 41(1):36-55. PubMed ID: 32584199
[TBL] [Abstract][Full Text] [Related]
12. Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.
Chaudhary JK; Yadav R; Chaudhary PK; Maurya A; Kant N; Rugaie OA; Haokip HR; Yadav D; Roshan R; Prasad R; Chatrath A; Singh D; Jain N; Dhamija P
Cells; 2021 Oct; 10(11):. PubMed ID: 34831172
[TBL] [Abstract][Full Text] [Related]
13. Emergence, evolution, and vaccine production approaches of SARS-CoV-2 virus: Benefits of getting vaccinated and common questions.
Hassanin AA; Haidar Abbas Raza S; Ahmed Ujjan J; Aysh ALrashidi A; Sitohy BM; Al-Surhanee AA; Saad AM; Mohamed Al-Hazani T; Osman Atallah O; Al Syaad KM; Ezzat Ahmed A; Swelum AA; El-Saadony MT; Sitohy MZ
Saudi J Biol Sci; 2022 Apr; 29(4):1981-1997. PubMed ID: 34924802
[TBL] [Abstract][Full Text] [Related]
14. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G
J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359
[TBL] [Abstract][Full Text] [Related]
15. SARS-CoV-2: Unique Challenges of the Virus and Vaccines.
Mahmoodpoor A; Sanaie S; Samadi P; Yousefi M; Nader ND
Immunol Invest; 2021 Oct; 50(7):802-809. PubMed ID: 34109900
[TBL] [Abstract][Full Text] [Related]
16. Elucidation of cellular targets and exploitation of the receptor-binding domain of SARS-CoV-2 for vaccine and monoclonal antibody synthesis.
Baig AM; Khaleeq A; Syeda H
J Med Virol; 2020 Nov; 92(11):2792-2803. PubMed ID: 32573788
[TBL] [Abstract][Full Text] [Related]
17. Mapping the technological landscape of SARS, MERS, and SARS-CoV-2 vaccines.
Nascimento Júnior JAC; Santos AM; Cavalcante RCM; Quintans-Júnior LJ; Walker CIB; Borges LP; Frank LA; Serafini MR
Drug Dev Ind Pharm; 2021 Apr; 47(4):673-684. PubMed ID: 33826439
[TBL] [Abstract][Full Text] [Related]
18. Interpretative immune targets and contemporary position for vaccine development against SARS-CoV-2: A systematic review.
Chauhan N; Soni S; Gupta A; Aslam M; Jain U
J Med Virol; 2021 Apr; 93(4):1967-1982. PubMed ID: 33270225
[TBL] [Abstract][Full Text] [Related]
19. COVID-19: Coronavirus Vaccine Development Updates.
Zhao J; Zhao S; Ou J; Zhang J; Lan W; Guan W; Wu X; Yan Y; Zhao W; Wu J; Chodosh J; Zhang Q
Front Immunol; 2020; 11():602256. PubMed ID: 33424848
[TBL] [Abstract][Full Text] [Related]
20. Latest in COVID-19 Vaccine 'Candidates' Race.
Atoum MF; Zreig DA; Abu Zreig LM
Infect Disord Drug Targets; 2023; 23(1):e180822207640. PubMed ID: 35984031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
